Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life

Inclusion Criteria

• •18 years of age or older
• •Diagnosis of squamous cell carcinoma of the oropharynx confirmed by the pathology department at MSKCC
• •Completed last treatment for oropharynx cancer (surgery, chemotherapy, or radiation) at least 12 months and no more than 5 years before the date of study enrollment
• •Known tumor status or tumor available for HPV testing \[based on chromogenic in situ hybridization with wide spectrum HPV probe (HPV III family 16 probe (Ventana) with affinity to HPV genotypes 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, and 66) or p16 immunohistochemistry done in a Clinical Laboratory Improvement Amendment (CLIA)-approved laboratory; if either of these 2 tests are positive, the patient is classified as positive\].
• •Able to speak and read English (study questionnaire-Aim 1 and interview guide-Aim 2 are currently only available in English).
• •Received at least one component of treatment for oropharynx cancer at MSKCC or the regional network sites
• •If radiation therapy was part of treatment, it must have been delivered at MSKCC or the regional network sites
• •For Aim 2 only, diagnosed with an HPV+ oropharynx cancer and have knowledge of this diagnosis prior to study enrollment